Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Telomir Pharmaceuticals (NASDAQ:TELO) in a research report report published on Friday, MarketBeat.com reports. The firm issued a buy rating and a $15.00 price target on the stock.

Telomir Pharmaceuticals Price Performance

Shares of TELO stock opened at $3.91 on Friday. The stock has a market capitalization of $116.36 million and a PE ratio of -6.74. Telomir Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $9.54. The business has a 50-day moving average of $4.54 and a 200 day moving average of $4.87.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). Analysts anticipate that Telomir Pharmaceuticals will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Nuveen Asset Management LLC purchased a new stake in Telomir Pharmaceuticals in the 4th quarter worth approximately $103,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Telomir Pharmaceuticals by 279.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company’s stock worth $44,000 after buying an additional 7,879 shares during the period. Gotham Asset Management LLC purchased a new stake in Telomir Pharmaceuticals in the 4th quarter worth approximately $28,000. Bank of America Corp DE lifted its holdings in Telomir Pharmaceuticals by 283.9% in the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock worth $61,000 after buying an additional 10,880 shares during the period. Finally, Northern Trust Corp raised its position in shares of Telomir Pharmaceuticals by 211.5% in the 4th quarter. Northern Trust Corp now owns 151,628 shares of the company’s stock worth $625,000 after acquiring an additional 102,948 shares in the last quarter.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.